Prostatitis

Clinical Snapshot

Prostatitis is inflammation of the prostate gland, and despite the single name it is not one disease but four genuinely distinct clinical entities grouped under the National Institutes of Health (NIH) consensus classification system.^[1] Getting the category right at the first visit is what actually drives everything downstream — the four categories differ completely in urgency, workup, and treatment duration, and treating one as if it were another is one of the most common ways this condition is mismanaged.

NIH category	Name	Defining feature
I	Acute bacterial prostatitis (ABP)	Severe prostatitis symptoms with systemic infection and acute bacterial urinary tract infection
II	Chronic bacterial prostatitis (CBP)	Chronic bacterial infection of the prostate, with or without symptoms, usually with recurrent UTIs caused by the same strain
IIIA / IIIB	Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)	Chronic pelvic pain, present for at least 3 of the preceding 6 months, with or without inflammatory changes, in the absence of a demonstrable urinary tract infection
IV	Asymptomatic inflammatory prostatitis (AIP)	Prostate inflammation found incidentally, with no genitourinary tract symptoms at all

^[1]

Almost 9% of Canadian men experience some prostatitis symptoms over the course of a year, and in about 6% those symptoms are a genuine bother; roughly a third experience a remission of symptoms within a year of follow-up.^[1] Men with clinically significant prostatitis symptoms account for about 3% of Canadian male outpatient visits.^[1] In the United States, chronic prostatitis alone accounts for roughly 2 million outpatient visits annually and is the third most commonly diagnosed urologic disease overall, and the single most prevalent urologic diagnosis in men under 50 — about 5% of men aged 20-50 have been affected at some point, though only around 60% of symptomatic men actually seek care.^[2] Less than 10% of all prostatitis is truly bacterial (Categories I and II); the great majority — roughly 90% — is CP/CPPS (Category III), a genuine diagnosis of exclusion rather than an infection.^[1]^[2]

Prostatitis is neither benign prostatic hyperplasia (BPH) nor a routine urinary tract infection, and it is worth distinguishing all three before treatment starts. BPH is a nonmalignant, androgen-dependent enlargement of prostate tissue that produces gradually progressive voiding symptoms without pain, fever, or a tender gland on examination — see the Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia chapter for its full workup and treatment. BPH and prostatitis can genuinely coexist (bladder outlet obstruction from BPH is itself a recognized risk factor for ascending infection), but BPH does not, on its own, explain pain, fever, or a tender/boggy prostate.^[1] Isolated cystitis is also genuinely uncommon in men, precisely because the prostate sits along the same anatomic pathway as the lower urinary tract; a febrile urinary tract infection, or one with a recurrent-relapse pattern, in a man should raise real suspicion of prostatic involvement rather than being managed as routine bladder infection (see Assessment & Diagnosis and Choose Initial Treatment).^[1]

Two threads run through this entire chapter because they are where a pharmacist's input is most likely to change what actually happens: the pharmacokinetic reason fluoroquinolones are preferred for prostate infections over agents that otherwise look reasonable on a spectrum-of-activity basis (see Choose Initial Treatment), and the practical counselling point that recent ejaculation or prostatic manipulation can transiently raise a PSA result enough to cause real, avoidable alarm in a man being worked up for something else entirely (see Assessment & Diagnosis and Special Populations).

Recognize the Condition

The four NIH categories in detail

Category I — Acute bacterial prostatitis (ABP)

ABP is a genuine systemic illness, not just a local prostate problem: fever, chills, malaise, and myalgias accompany irritative and obstructive voiding symptoms (dysuria, frequency, urgency, hesitancy, a weak stream) and perineal, suprapubic, or low-back pain, with generalized urosepsis a real, current risk while it is untreated.^[1]^[3] Onset is acute, over hours to a few days — a genuinely different timeline from the gradual, progressive course of BPH-related symptoms or the months-long pattern of CP/CPPS.^[3] Escherichia coli causes roughly 50-90% of cases; other Enterobacteriaceae (Proteus, Klebsiella, Enterobacter, Serratia) and Pseudomonas account for most of the rest.^[3] Most cases are ascending infections from urethritis or cystitis, though direct inoculation from prostate biopsy or urologic instrumentation is also a recognized route.^[3] ABP responds promptly to antimicrobial therapy in most patients and is usually self-limiting once treated — this is what makes it the one true emergency in this chapter, not a condition that can safely wait.^[1]

Category II — Chronic bacterial prostatitis (CBP)

CBP is a genuine, culture-documented bacterial infection of the prostate, but a much quieter one than ABP: mild-to-moderate pelvic pain with intermittent episodes of acute, culture-proven urinary tract infection — typically caused by the same bacterial strain each time, since the underlying problem is a persistent bacterial reservoir within the gland rather than a series of unrelated new infections.^[1] Between episodes, many men are entirely asymptomatic, which is exactly why CBP is under-recognized until a recurrence pattern is specifically asked about.^[2] E. coli is again the leading organism; prostatic calculi are a genuinely important and easily missed contributor, since bacterial biofilm forms on the surface of these stones and provides an ongoing reservoir that is very difficult for antibiotics — or the immune system — to fully clear.^[2] Long-term antimicrobial therapy is curative in roughly 60-80% of patients, and that success rate is directly tied to using an adequately long course (see Choose Initial Treatment) — the single most common reason for treatment failure in this category is a course that was simply too short.^[1]

Category III — Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

CP/CPPS is, by a wide margin, the category most pharmacists and prescribers will actually see — most men referred to a urologist with "chronic prostatitis" turn out to have this, not a bacterial infection.^[1] It is defined as chronic pelvic pain — perineal, suprapubic, testicular, or penile — present for at least 3 of the preceding 6 months, with variable urinary symptoms and frequent sexual dysfunction (primarily pain associated with ejaculation), in the absence of a demonstrable urinary tract infection.^[1] Pelvic pain, particularly with ejaculation, is in fact the single most common presenting symptom overall, reported by roughly 70% of patients.^[2] The category splits further into IIIA (inflammatory), with significant leukocytosis in prostate-specific specimens, and IIIB (non-inflammatory), without it — a distinction that matters less for treatment selection than it once did, since current management is organized around clinical phenotype (UPOINT) rather than inflammatory subtype alone (see Assessment & Diagnosis).^[1] The underlying mechanism is genuinely not fully understood: proposed contributors include occult or atypical infection, autoimmune activity, dysregulated immune responsiveness, neuropathic sensitization of peripheral and central pain pathways following an initiating event, and psychological factors — none proven as a single unifying cause, which is exactly why CP/CPPS does not respond reliably to any single-target drug (see Choose Initial Treatment).^[2]

Category IV — Asymptomatic inflammatory prostatitis (AIP)

AIP is prostate inflammation — leukocytes or bacteria — found incidentally on a specimen obtained for an unrelated reason (a semen analysis, a prostate biopsy, expressed prostatic secretions checked for another indication), in a man with no genitourinary symptoms at all.^[1] Some evidence suggests this category may have real biologic relevance, but at present there is no evidence that identifying it changes outcomes, and it does not, by definition, require treatment.^[1]

Risk Factors

Recent urologic instrumentation, catheterization, cystoscopy, or prostate biopsy — a direct-inoculation route specifically for acute bacterial prostatitis.^[3]
Unprotected intercourse, a new sexual partner, or other sexually transmitted infection risk factors — relevant to STI-likely ABP etiology in younger, sexually active men (see Choose Initial Treatment).^[3]
Phimosis and intraprostatic ductal reflux.^[3]
Benign prostatic hyperplasia or another cause of bladder outlet obstruction — predisposes to ascending infection via urinary reflux and is itself part of the differential to keep straight (see Assessment & Diagnosis).^[3]
Diabetes and other causes of immunosuppression — raise both infection risk and the threshold for hospitalizing a case of ABP.^[3]^[1]
An indwelling catheter.^[3]
Recurrent culture-proven urinary tract infections, especially with the same organism each time — the hallmark risk pattern for chronic bacterial prostatitis.^[1]
Prostatic calculi — a genuinely important, easily missed contributor to relapsing chronic bacterial prostatitis, since bacterial biofilm on the stone surface resists both antibiotics and host clearance.^[2]
Psychological stress, anxiety, depression, maladaptive coping (catastrophizing), and poor social support — genuine risk and symptom-severity factors specifically for CP/CPPS, not incidental comorbidities.^[1]
Pelvic floor myofascial dysfunction and trigger points — a perpetuating factor for the Tenderness domain of CP/CPPS.^[2]
Smoking — smokers are more likely to have chronic prostatitis than non-smokers.^[2]
Age under 50 for CP/CPPS specifically, versus any adult age for acute or chronic bacterial prostatitis.^[2]

Red Flags & Refer

Any of the following in a man with suspected acute bacterial prostatitis is an indication for hospitalization or emergent escalation, not outpatient management:

Hyperpyrexia, prolonged vomiting, severe dehydration, tachycardia, tachypnea, hypotension, or other features of urosepsis — hospitalization is mandatory.^[1]
High-risk features even without frank urosepsis: diabetes, immunosuppression, older age, a suspected prostatic abscess, or severe voiding disorder — hospitalization is recommended.^[1]
Severe obstructive voiding symptoms or frank urinary retention — needs prompt, gentle urinary drainage (see Non-Pharmacologic Treatment).^[1]
No defervescence and clinical improvement within 48-72 hours of appropriate antibiotics — image to rule out a prostatic abscess rather than simply extending the same regimen.^[1]

Other red flags, any category

An abnormal digital rectal examination — a hard, nodular, or asymmetric prostate — should never be assumed to be prostatitis; it needs the same prostate-cancer workup it would in any other context.^[1]
Gross or unexplained hematuria needs its own evaluation to exclude bladder or upper-tract pathology rather than being attributed to prostatitis by default.
Rapidly spreading perineal erythema, crepitus, disproportionate pain, or systemic toxicity out of proportion to the apparent infection — consider Fournier's gangrene, a surgical emergency requiring immediate referral, not outpatient antibiotic escalation.
Severe depression or suicidal ideation in a man with CP/CPPS — referral to a psychologist or psychiatrist is mandatory, not optional, given the genuine, well-documented psychosocial burden of this condition.^[1]

Assessment & Diagnosis

History

A comprehensive history is mandatory for every patient: pain location, severity, frequency, and duration; lower urinary tract symptoms, both obstructive/voiding and irritative/storage; associated symptoms (fever, other pain syndromes); and impact on activities and quality of life. A full systems review should document past medical and surgical (particularly urologic) history, trauma, medications, and allergies.^[1]

Physical examination

The abdomen, external genitalia, perineum, and prostate must be examined in every category, and the pelvic floor specifically in suspected CBP and CP/CPPS.^[1]

Prostate massage during a digital rectal examination is not recommended when acute bacterial prostatitis is suspected — vigorous manipulation of an acutely infected gland can precipitate bacteremia and acutely worsen the patient's condition; a gentle examination to assess tenderness is appropriate, but stop there.^[1]^[3] This caution is specific to suspected ABP — once ABP has been excluded, gentle prostatic massage is not only safe but a genuinely necessary part of the 4-glass/2-glass localization test used to diagnose CBP and phenotype CP/CPPS (see below).

Feature	Acute bacterial prostatitis	BPH-related LUTS	Prostate cancer	Cystitis/UTI in a man
Onset	Acute, hours to days, with fever/systemic illness	Gradual, over years	Often asymptomatic; LUTS occurs late, with locally advanced disease	Acute, but without the systemic toxicity or prostate tenderness of ABP
DRE	Exquisitely tender, boggy, warm — avoid vigorous massage	Smooth, firm, symmetrically enlarged, nontender	Firm/hard nodule, asymmetry, induration	Normal, nontender prostate
PSA	Often markedly elevated — not diagnostically useful; recheck only well after treatment	May be mildly elevated, proportional to gland volume	Markedly elevated or rapidly rising	Usually normal or only mildly elevated
Key distinguishing clue	Fever, systemic toxicity, exquisite prostate tenderness	Gradual voiding symptoms, normal urinalysis — see the Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia chapter	Abnormal DRE and/or markedly elevated or rapidly rising PSA	Isolated cystitis is uncommon in men — a febrile or recurrent UTI should raise real suspicion of prostatic involvement rather than being treated as routine cystitis

^[1]^[3]

Urinalysis and culture

Mandatory in acute bacterial prostatitis.^[1] A midstream culture is the starting point for every category and, together with a recurrent-UTI history, decides whether localization testing (below) is needed.

The 4-glass test and 2-glass pre- and post-massage test (PPMT)

Specimen	What it represents	How it's collected
VB1	Urethral flora	First 10 mL of voided urine
VB2	Bladder flora	Midstream urine
EPS	Prostatic secretions	Expressed by gentle prostatic massage
VB3	Prostatic flora flushed by voiding	First 10 mL voided immediately after the massage

A bacterial count at least 10-fold higher in EPS or VB3 than in VB1 or VB2 localizes infection to the prostate and confirms chronic bacterial prostatitis rather than CP/CPPS; the 4-glass test is the diagnostic criterion standard.^[1]^[2] The simpler 2-glass PPMT, comparing only a pre-massage and a post-massage specimen, offers similar diagnostic accuracy with far less complexity and is a reasonable, more practical default.^[1]^[2] Microscopy of EPS/urine sediment is optional and adds no proven clinical value on its own.^[1] Semen culture is not recommended — it has not been shown to meaningfully help identify CBP unless it grows the same organism responsible for recurrent UTIs.^[1]

NIH-Chronic Prostatitis Symptom Index (NIH-CPSI)

The internationally standard, validated tool for grading current CP/CPPS symptom severity and tracking response to therapy — a symptom index, not a diagnostic test on its own.^[1]

Domain	What it captures	Score range
Pain or discomfort	Location (perineum, testicles, tip of penis, pubic/bladder area), pain/burning with urination, pain/discomfort with ejaculation, and the frequency and average severity of pain over the past week	0-21
Urinary symptoms	Incomplete emptying and urinary frequency (urinating again within 2 hours) over the past week	0-10
Quality of life impact	How much symptoms interfered with usual activities, how much the patient thought about symptoms, and how the patient would feel living with these symptoms indefinitely	0-12

Total score (0-43) is conventionally categorized as mild (0-14), moderate (15-29), or severe (30-43).^[1]^[2]

UPOINT phenotyping

Once CP/CPPS is diagnosed, individualized personal therapy directed at a clinically defined phenotype — UPOINT — organizes the entire treatment approach (see Choose Initial Treatment and Pharmacologic Treatment Options); a multimodal approach using specific clinical phenotypes to choose therapies is a genuine, evidence-supported recommendation, since monotherapy provides at best modest efficacy.^[1]

Domain	Positive when...	Directed therapy
U — Urinary	Bothersome storage/voiding symptoms, increased post-void residual, dysuria	Diet modification, alpha-blockers, urinary analgesics, antimuscarinics/beta-3 agonists
P — Psychosocial	Depression, maladaptive coping/catastrophizing, social dysfunction, stress, anxiety	Cognitive behavioural therapy, counselling, antidepressants, anxiolytics
O — Organ-specific	Localized prostate tenderness/leukocytosis, hematospermia, extensive prostatic calcification, lower urinary tract obstruction	Phytotherapy, alpha-blockers, a 5-alpha-reductase inhibitor in older men with an enlarged gland, prostate-directed procedures
I — Infection	A uropathogen identified in a post-massage specimen, prior UTI, prior response to antibiotics	Antibiotics — only when an actual pathogen is identified, not as a repeated empiric trial
N — Neurologic/systemic	Extraprostatic neuropathic-type pain, associated conditions (irritable bowel syndrome, fibromyalgia)	Gabapentinoids, amitriptyline, neuromodulation
T — Tenderness	Palpable tenderness, painful spasm, or trigger points in the pelvis, perineum, or abdomen on exam	Pelvic floor physical therapy, muscle relaxants, targeted exercises

^[1]

Imaging, cystoscopy, urodynamics, and serum PSA

Transrectal ultrasound and CT are not recommended as routine initial workup for any category; TRUS or CT becomes appropriate specifically in ABP refractory to initial therapy, to rule out a prostate abscess.^[1] Cystoscopy is not recommended for routine CP/CPPS evaluation, but is reasonable in selected patients with obstructive voiding symptoms refractory to medical therapy, hematuria, or other suspected lower urinary tract pathology.^[1] Urodynamics/uroflow are optional adjuncts to confirm obstruction, not to differentiate prostatitis categories from each other.^[1] Serum PSA is not recommended in ABP (an elevated result usually just causes confusion and worry) nor routinely in CP/CPPS (it does not help diagnose the condition or direct therapy) — indications for PSA testing in a man with CP/CPPS should be the same as for any other man.^[1]

Before drawing any PSA sample in a man being worked up for prostate symptoms, ask about recent ejaculation and any recent prostatic manipulation. Ejaculation alone causes a significant, transient rise in serum PSA — increasing in the large majority of men, peaking within about an hour, and returning to baseline in most men within 48 hours; the standard recommendation is to abstain from ejaculation for at least 48 hours before a PSA sample is drawn.^[4] Active prostatic infection or inflammation, and prostatic massage/manipulation, cause an even larger and longer-lived rise — up to roughly 70% of men with active infection or inflammation have an elevated PSA, and a waiting period of at least 6 weeks after the infection or inflammation has resolved is recommended before a PSA result can be meaningfully interpreted.^[2] A PSA drawn without accounting for either of these is a genuinely common, entirely avoidable source of unnecessary alarm — and, in the worst case, an unnecessary biopsy referral — in a man who does not actually have a rising, cancer-related PSA at all.

Psychological assessment

Optional but genuinely relevant: accumulating evidence shows psychosocial parameters — depression, maladaptive coping mechanisms, poor social support — impact both symptoms and treatment results, and screening for them is part of a complete CP/CPPS assessment.^[1] Referral is mandatory, not optional, for severe depression or suicidal ideation.^[1]

Treatment Targets

Eradicate the infection and prevent progression to urosepsis or abscess in acute bacterial prostatitis.
Eradicate the infection and prevent relapse in chronic bacterial prostatitis, using a course long enough to actually achieve that (see Choose Initial Treatment).^[1]
Reduce pain and improve quality of life in CP/CPPS through an individualized, phenotype-directed multimodal approach, since no single agent reliably works and monotherapy provides at best modest efficacy.^[1]
Correctly differentiate prostatitis from BPH, prostate cancer, and routine UTI before committing to a treatment pathway (see Assessment & Diagnosis).
Avoid unnecessary or prolonged antibiotic use — particularly repeated empiric courses in CP/CPPS with no documented pathogen.^[1]^[5]
Screen for and address the psychosocial contributors to CP/CPPS as an actual treatment target, not an afterthought.^[1]
Preserve fertility and sexual function where possible, and treat category IV only when a specific, indicated reason exists (elevated PSA, infertility workup, pre-biopsy).^[1]

Choose Initial Treatment

Direct treatment rule

Match therapy to the NIH category — never treat CP/CPPS like a routine infection, and never treat ABP like a chronic condition that can wait

Category I — severe illness, urosepsis, or a high-risk feature (diabetes, immunosuppression, older age, prostatic abscess, severe voiding disorder) hospitalize; empiric IV therapy — an aminoglycoside plus ampicillin, a broad-spectrum penicillin plus a beta-lactamase inhibitor (e.g., piperacillin-tazobactam), a third-generation cephalosporin, or an IV fluoroquinolone — continued until defervescence and resolution of urosepsis, then step down to an oral fluoroquinolone to complete 2-4 weeks total.^[1] Category I — not severely ill, tolerating oral intake an oral fluoroquinolone (levofloxacin) for 2-4 weeks; sulfamethoxazole-trimethoprim is no longer recommended as first-line empiric therapy where local E. coli resistance exceeds 10-20%.^[1] Category I — younger, sexually active man, STI-likely etiology Combo: ceftriaxone 250 mg IM single dose + doxycycline 100 mg PO twice daily for 14 days, mirroring this platform's Epididymitis chapter — the same ascending-STI logic applies when the infection has reached the prostate itself.^[3] Category II — chronic bacterial prostatitis a fluoroquinolone (levofloxacin) for 4-6 weeks is first-line given favourable prostate-tissue penetration (see below); a confirmed fluoroquinolone-resistant pathogen is treated with sulfamethoxazole-trimethoprim (or another susceptible agent) for a longer 8-12 weeks, and multidrug-resistant E. coli — including ESBL-producing strains — can be treated with oral fosfomycin, 3 g every 24 hours for 1 week then 3 g every 48-72 hours for a total of 6-12 weeks.^[1]^[6] Category III — CP/CPPS antimicrobials cannot be recommended for men with longstanding, previously treated CP/CPPS — repeated courses in the absence of a documented pathogen add resistance risk without benefit.^[1]^[5] A short 2- to 4-week trial is a reasonable option specifically in antimicrobial-naive, newly diagnosed patients, but the actual recommended approach is individualized, UPOINT-phenotype-directed multimodal therapy (see Assessment & Diagnosis, Non-Pharmacologic Treatment, and Pharmacologic Treatment Options) — treating CP/CPPS like a simple infection is one of the most common management errors in this entire chapter.^[1]^[5] Category IV — asymptomatic inflammatory prostatitis no treatment — this category is, by definition, asymptomatic; antimicrobial therapy is an optional consideration only for selected patients with an elevated PSA, an infertility workup, or before a planned prostate biopsy.^[1]

Why the antibiotic — and the duration — genuinely differs by category: prostate-tissue penetration pharmacokinetics

This is not an arbitrary prescribing preference. The prostate is protected by a blood-prostate barrier, and effective treatment of bacterial prostatitis is fundamentally limited by how well a given antibiotic actually crosses it — a function of the drug's lipophilicity, its degree of plasma protein binding, and, critically, pH-dependent ion trapping.^[7] Prostatic fluid is normally more acidic than plasma; a lipophilic weak base equilibrates across the barrier and becomes proportionally more ionized — and therefore effectively trapped — on the more acidic prostatic side, concentrating there relative to plasma, while a weak acid does the opposite and is comparatively excluded.^[7] Fluoroquinolones are the clearest beneficiary of this chemistry: their zwitterionic structure and lipophilicity give them consistently favourable intraprostatic penetration — prostate tissue-to-serum concentration ratios at or above 1, commonly 2- to 3-fold higher than plasma — which is exactly why the Canadian Urological Association identifies fluoroquinolones as the agents of choice for chronic bacterial prostatitis specifically because of their "unique and favourable pharmacokinetic properties."^[1]^[7] Trimethoprim-sulfamethoxazole penetrates only moderately, and that penetration is driven almost entirely by the trimethoprim component — sulfamethoxazole itself penetrates poorly, which blunts the synergy the combination normally relies on and is a real part of why it needs a longer course and is reserved as a second choice rather than being interchangeable with a fluoroquinolone.^[7] Most beta-lactams — penicillins and most cephalosporins — penetrate poorly into non-inflamed prostate tissue, since they are ionized weak acids largely excluded by the same pH gradient; selected cephalosporins can still achieve moderate concentrations specifically in the setting of acute inflammation, which disrupts the barrier and increases local permeability.^[7] That last point is exactly why the two bacterial categories are treated so differently: acute bacterial prostatitis is, by definition, an acutely inflamed gland with a genuinely more permeable barrier, which is why empiric IV beta-lactam/aminoglycoside regimens still work well for severe ABP even though those same drugs would be a poor choice for a chronically, non-acutely inflamed gland — and chronic bacterial prostatitis has a comparatively intact barrier and often a biofilm-protected bacterial reservoir on prostatic calculi, which is why CBP specifically needs an agent with genuinely good baseline penetration (a fluoroquinolone) continued for a genuinely long course rather than the shorter 2-4 week course that suffices once the acute inflammatory window of ABP has already improved the drug's access to the tissue.^[7]^[1]

Non-Pharmacologic Treatment

Acute bacterial prostatitis

Adequate hydration and antipyretic/analgesic support (see Pharmacologic Treatment Options) while antibiotics take effect.
A single catheterization with a trial of voiding, or a short-term small-caliber urethral catheter, for severe obstructive voiding symptoms or urinary retention; a suprapubic tube is a reasonable option for a patient who cannot tolerate a urethral catheter.^[1]
Incision and drainage — most often via a transurethral approach, though perineal, rectal, or transperineal routes are also used — for a confirmed prostatic abscess that does not respond to antibiotics alone.^[1]
Activity modification and rest during the acute, systemically unwell phase.

Chronic bacterial prostatitis

Adherence counselling is genuinely the single highest-yield non-drug intervention here — the entire rationale for a 4- to 12-week course is incomplete tissue penetration, and stopping early once symptoms improve is the most common reason for relapse (see Common Errors to Avoid).
Identify and address underlying risk factors that perpetuate infection: bladder outlet obstruction, phimosis, and — genuinely important and easy to miss — prostatic calculi, which harbour bacterial biofilm and can require surgical management (radical TURP or open/simple prostatectomy) as a genuine last resort when every other option has failed.^[1]^[2]

Chronic prostatitis/chronic pelvic pain syndrome

Hot sitz baths — about 10 minutes is usually sufficient, and most patients find several a day genuinely helpful for symptomatic relief.^[2]
A soft cushion or inflatable "donut," avoiding prolonged bicycle riding, and avoiding sitting on cold, hard surfaces — all reduce direct perineal pressure that can aggravate pelvic floor and prostatic pain.^[2]
Dietary trigger identification — caffeine reduction is close to a universal recommendation, and reducing alcohol, spicy food, and citrus is reasonable to trial; frame this the same way this platform's Interstitial Cystitis chapter does — as an individualized elimination-and-reintroduction exercise to find a given patient's own triggers, not a rigid universal diet.^[2]
Manual pelvic floor physical therapy — myofascial trigger-point release and paradoxical relaxation techniques — is most useful specifically for men with a positive Tenderness (T) domain on UPOINT phenotyping (palpable pelvic floor tenderness, spasm, or trigger points).^[2]
Regular, scheduled ejaculation — commonly advised at least once every 3 days — is thought to reduce prostatic fluid stasis and ductal buildup; prostatic massage as a treatment in its own right remains genuinely controversial with conflicting evidence, so scheduled ejaculation is the more practical, better-tolerated alternative to advise.^[2]
Smoking cessation — smokers are more likely to have chronic prostatitis than non-smokers.^[2]
Regular exercise has shown symptom improvement in at least one randomized study, and stress reduction and sleep optimization are reasonable general measures given the strong link between CP/CPPS symptom severity and psychological stress.^[2]
Psychological support, ideally including a cognitive behavioural therapy component, should be considered for the Psychosocial (P) UPOINT domain; referral to a psychologist or psychiatrist is mandatory, not optional, for a patient with severe depression or suicidal ideation.^[1]
Acupuncture has shown good efficacy for CP/CPPS symptoms in several studies, particularly when combined with other treatment modalities.^[2]

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Levofloxacin Preferred	First-line oral fluoroquinolone, ABP (outpatient) and CBP	ABP: 500 mg PO once daily for 2-4 weeks. CBP: 500 mg PO once daily for 4-6 weeks	GI upset, tendinopathy risk, QTc prolongation, peripheral neuropathy	Achieves favourable prostate-tissue penetration (see Choose Initial Treatment for the pharmacokinetic explanation).
Ciprofloxacin Alternative	Historically the most-studied fluoroquinolone for prostatitis	500 mg PO twice daily for the durations above	GI upset, tendinopathy, QTc prolongation, CNS effects	Only combination ciprofloxacin products exist in this platform's drug database — presented here unlinked; levofloxacin's once-daily dosing and confirmed availability make it the more practical default.
Sulfamethoxazole-Trimethoprim Alternative	Fluoroquinolone-resistant ABP/CBP, or confirmed local resistance under 10-20%	ABP: 1 DS tablet (800/160 mg) PO twice daily for 2-4 weeks. CBP: same dose for 8-12 weeks	Rash, hyperkalemia, hematologic effects, photosensitivity	No longer first-line empiric therapy where local E. coli resistance exceeds 10-20%; penetration is driven mainly by the trimethoprim component (see Choose Initial Treatment).
Piperacillin-Tazobactam Special situation	Severe/hospitalized ABP with urosepsis, initial parenteral therapy	3.375-4.5 g IV every 6-8 hours until defervescence, then step down to oral	GI upset, hypersensitivity, electrolyte disturbances	One of several acceptable IV options for initial empiric coverage of severe ABP.
Ceftriaxone Special situation	Severe/hospitalized ABP; also the STI-coverage component when paired with doxycycline	1-2 g IV/IM once daily until defervescence (severe ABP); 250 mg IM single dose when paired with doxycycline	Injection-site pain, hypersensitivity, rare biliary sludging	Does not reliably cover Pseudomonas — confirm local antibiogram/culture in severe or refractory disease.
Gentamicin Special situation	Severe/hospitalized ABP, combined with ampicillin for broad empiric coverage	Weight-based IV dosing per local protocol, with therapeutic drug monitoring	Nephrotoxicity, ototoxicity	Requires renal function monitoring; step down to an oral agent once culture results and clinical improvement allow.
Doxycycline Special situation	STI-likely ABP in a younger, sexually active man, paired with ceftriaxone	100 mg PO twice daily for 14 days	GI upset, photosensitivity, esophageal irritation	Mirrors this platform's Epididymitis chapter regimen — complete the full course even once symptoms improve.
Fosfomycin Special situation	Multidrug-resistant, including ESBL-producing, E. coli CBP	3 g PO every 24 hours for 1 week, then 3 g PO every 48-72 hours for a total of 6-12 weeks	GI upset, headache	Achieves adequate prostatic tissue concentrations by a mechanism independent of the ion-trapping pathway fluoroquinolones rely on.
Tamsulosin Alternative	Obstructive voiding symptoms in ABP; UPOINT Urinary domain in CP/CPPS	0.4 mg PO once daily	Dizziness, retrograde ejaculation	In ABP, reduces retention risk rather than treating infection; in CP/CPPS, must be continued at least 6 (likely 12) weeks and works best as part of multimodal therapy, not monotherapy.
Alfuzosin Alternative	Alpha-blocker alternative, same indications as tamsulosin	10 mg PO once daily after the same meal each day	Dizziness, headache, fatigue	The best-studied alpha-blocker specifically in CP/CPPS randomized trials.
Ibuprofen Alternative	Pain/fever adjunct in ABP; adjunctive analgesia in CP/CPPS	400-600 mg PO every 6-8 hours with food	GI upset/bleeding risk, renal effects with prolonged use	Anti-inflammatory therapy is not recommended as primary CP/CPPS treatment alone, but is reasonable within a multimodal plan.
Naproxen Alternative	Same role as ibuprofen	250-500 mg PO twice daily with food	GI upset/bleeding risk, renal effects with prolonged use	Longer dosing interval alternative to ibuprofen.
Amitriptyline Alternative	CP/CPPS Neurologic/systemic UPOINT domain — neuropathic-type pain	Low, chronic-pain-range dose per product monograph, titrated to tolerability	Anticholinergic effects, sedation, dry mouth	Not primary monotherapy — selected specifically for men whose pain has a neuropathic quality.
Pregabalin Alternative	CP/CPPS Neurologic/systemic UPOINT domain	Per product monograph, titrated to tolerability and renal function	Dizziness, somnolence, peripheral edema	The specific agent studied in a randomized controlled trial for CP/CPPS-associated pain; gabapentin is a reasonable class alternative.
Finasteride Special situation	CP/CPPS Category IIIA in older men with an enlarged prostate, as part of a multimodal plan	5 mg PO once daily for at least 6 months before judging effect	Sexual dysfunction; rare serious muscle-related effects	Not primary monotherapy — see the Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia chapter for the full 5-alpha-reductase inhibitor counselling points, which apply identically here.
Acetaminophen Alternative	Analgesia when an NSAID is contraindicated, any category	500-1000 mg PO every 6 hours, maximum 4 g/day (lower in hepatic impairment)	Hepatotoxicity with overdose or significant hepatic impairment	Does not address the inflammatory component — pair with other multimodal measures.

Special Populations

Younger, sexually active men

STI-likely acute bacterial prostatitis is managed the same way this platform's Epididymitis chapter manages STI-likely epididymitis — ceftriaxone plus doxycycline, with partner notification and empiric partner treatment for the 60 days preceding symptom onset, abstinence until treatment is complete and symptoms have resolved, and reinfection screening at 6 months. See that chapter for the full partner-management protocol; the same underlying ascending-STI logic applies here.^[3]

Men over 50

CP/CPPS Category IIIA in an older man with a demonstrably enlarged prostate is one of the few situations where a 5-alpha-reductase inhibitor has a genuine, if secondary, role — not as primary monotherapy, but as part of a multimodal plan, given at least 6 months before judging effect.^[1] An episode of acute or chronic bacterial prostatitis in this age group should also prompt evaluation for underlying bladder outlet obstruction from BPH once the acute infection has resolved — see the Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia chapter for that workup.

Men with recurrent instrumentation, indwelling catheters, or nursing-home residence

These men carry a materially higher risk of resistant organisms — Pseudomonas aeruginosa and Enterococcus species show a poorer response to standard antimicrobial therapy than E. coli and other Enterobacteriaceae — so culture-directed rather than purely empiric therapy, and a broader initial empiric regimen while cultures are pending, are both reasonable.^[1]

Men undergoing or considering PSA-based evaluation

Serum PSA is not recommended as a routine part of the prostatitis workup itself — an elevated PSA in ABP usually just causes confusion and worry, and PSA does not help diagnose or direct therapy in CP/CPPS.^[1] But when a PSA result is genuinely needed — for an unrelated, appropriately indicated prostate-cancer risk discussion happening around the same time — two confounders specifically need to be accounted for: recent ejaculation (advise at least 48 hours of abstinence beforehand) and active or recent prostatic infection/inflammation (wait at least 6 weeks after resolution before interpreting a result).^[4]^[2] See Assessment & Diagnosis for the full counselling point, and the Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia chapter for the separate PSA-interpretation nuance created by 5-alpha-reductase inhibitor therapy.

Men with infertility

Chronic bacterial prostatitis and CP/CPPS are both associated with impaired sperm concentration, motility, and morphology.^[2] Category IV found incidentally during an infertility workup is one of the specific situations where antimicrobial therapy is a reasonable, optional consideration despite the complete absence of symptoms.^[1]

Severe psychiatric comorbidity

Referral to a psychologist or psychiatrist is mandatory, not optional, for any CP/CPPS patient with severe depression or suicidal ideation — this reflects genuine, evidence-based psychosocial modelling of the syndrome, not a generic add-on recommendation.^[1]

Monitoring & Follow-Up

Acute bacterial prostatitis: expect defervescence and clear clinical improvement within 48-72 hours of appropriate antibiotics; if this does not occur, image (TRUS or CT) to rule out a prostatic abscess rather than simply extending the same regimen.^[1] Complete the full 2-4 week course even once symptoms resolve, and consider evaluating for underlying bladder outlet obstruction once the acute episode has resolved, particularly in a man over 50.
Chronic bacterial prostatitis: clinical improvement is typically seen within the first 1-2 weeks, but the full 4- to 12-week course (depending on the agent and organism) must be completed regardless — this is genuinely the single most important adherence message in this chapter, since premature discontinuation is the leading cause of relapse.^[1] For a treatment-refractory patient with a confirmed uropathogen still localized to the prostate, reasonable strategies include intermittent antimicrobial treatment of acute symptomatic recurrences, low-dose antimicrobial suppression, or — genuinely a last resort, and only if every other option has failed — radical TURP or open/simple prostatectomy.^[1]
CP/CPPS: reassess the NIH-CPSI periodically to track objective response rather than relying on unprompted recall, and revisit the UPOINT phenotype at follow-up, since a patient's dominant domain — and therefore the most useful next therapy — can shift over time.^[1] Reconsider the diagnosis itself — including a repeat localization culture to exclude a missed chronic bacterial component — if a patient fails to improve despite multiple, adequately trialled multimodal approaches, rather than continuing to escalate indefinitely against a diagnosis that may need revisiting.^[2]
Any category: re-screen for depression, anxiety, and suicidal ideation at follow-up in a patient with persistent symptoms, given how strongly psychosocial burden and symptom severity are linked in this condition.^[1]^[2]

Treatment Failure / Next Step

Acute bacterial prostatitis not defervescing within 48-72 hours of appropriate antibiotics: image (TRUS or CT) to rule out a prostatic abscess; broaden or adjust the antibiotic based on culture and sensitivity results; drain any confirmed abscess.^[1]
Chronic bacterial prostatitis relapsing after an apparently complete course: first confirm the full course was actually completed and adherence was genuine before assuming true antimicrobial failure; repeat localization culture to confirm the organism and its susceptibility; switch to sulfamethoxazole-trimethoprim (fluoroquinolone-resistant organism, 8-12 weeks) or fosfomycin (multidrug-resistant E. coli, 6-12 weeks).^[1]^[6]
Chronic bacterial prostatitis genuinely refractory despite an adequately long, susceptibility-directed course: intermittent antimicrobial treatment of acute symptomatic recurrences, or low-dose antimicrobial suppression, are reasonable next steps; radical TURP or open/simple prostatectomy is a genuine last resort, reserved for when every other option has failed.^[1]
CP/CPPS not responding to an initial single-domain intervention (for example, an alpha-blocker alone): do not simply escalate that one drug's dose — move to genuinely multimodal, UPOINT-directed combination therapy across every positive domain, since monotherapy provides at best modest efficacy in this category.^[1]^[5]
CP/CPPS refractory despite an adequate multimodal trial: refer to a pain management specialist and/or a multidisciplinary team (urology, pelvic floor physical therapy, psychology); reconsider the diagnosis itself, including a repeat localization culture to exclude a missed chronic bacterial component and reassessment for interstitial cystitis or pelvic floor myalgia as the dominant driver.^[2]
Any new red flag at any point — urosepsis, an abnormal/hard/nodular DRE, gross hematuria, or suicidal ideation — escalate or refer immediately rather than continuing the current management plan.^[1]

Common Errors to Avoid

Performing a vigorous prostatic massage or DRE in a patient with suspected acute bacterial prostatitis — this can precipitate bacteremia and worsen the patient's condition; gentle examination only, and reserve prostatic massage for localization testing once ABP has been excluded.^[1]^[3]
Ordering or over-interpreting a PSA during active acute bacterial prostatitis, or without asking about recent ejaculation or prostatic manipulation — both are common, avoidable sources of a falsely alarming result (see Assessment & Diagnosis).^[1]^[4]^[2]
Defaulting to sulfamethoxazole-trimethoprim as first-line empiric therapy for acute bacterial prostatitis without knowing local E. coli resistance patterns.^[1]
Stopping chronic bacterial prostatitis antibiotics once symptoms improve rather than completing the full 4- to 12-week course — the entire rationale for that duration is incomplete tissue penetration, and early discontinuation is the single most common, and most avoidable, cause of relapse.^[1]
Prescribing repeated or prolonged antibiotic courses for CP/CPPS in a patient with a negative culture and no documented pathogen — current AUA guidance explicitly cautions against this, and it is not supported for men who have already failed a prior antibiotic trial.^[1]^[5]
Choosing moxifloxacin for a urinary tract or prostate infection — despite generally good tissue penetration, it achieves clinically inadequate urinary and prostatic fluid concentrations due to minimal renal excretion, and is not an appropriate substitute for levofloxacin in this indication.
Treating Category IV (asymptomatic inflammatory prostatitis) — by definition an incidental, symptom-free finding — as something that needs definitive antibiotic therapy.^[1]
Ordering a semen culture to try to "confirm" chronic bacterial prostatitis — it is not recommended, and a negative result does not rule CBP out.^[1]
Missing the psychosocial dimension of CP/CPPS and treating only the physical symptoms, rather than screening for depression, maladaptive coping, and social dysfunction as an actual UPOINT domain in its own right.^[1]
Confusing prostatitis, BPH, and a routine UTI without applying the actual distinguishing features — onset pattern, DRE findings, and systemic symptoms — rather than treating any pelvic/voiding complaint in a man as interchangeable with the other two (see Assessment & Diagnosis).^[1]

Clinical Decision Algorithm

Algorithm A — Initial presentation and NIH category triage

Man presents with pelvic/perineal pain, voiding symptoms, and/or fever

History (pain location/duration, LUTS, sexual/urologic history), gentle physical exam (abdomen, genitalia, perineum, gentle DRE only — no vigorous prostatic massage if ABP is suspected), urinalysis and midstream culture^[1]

Fever, systemic toxicity, exquisitely tender/boggy/warm prostate, acute onset over hours-days

Suspected acute bacterial prostatitis (Category I) — proceed to Algorithm B; do not perform prostatic massage^[1]^[3]

Recurrent culture-proven UTIs, same organism, mild/intermittent symptoms, no acute toxicity

Suspected chronic bacterial prostatitis (Category II) — proceed to Algorithm C for localization testing^[1]

Chronic pelvic pain for at least 3 of the preceding 6 months, no acute infection, urine culture negative

Suspected CP/CPPS (Category III) — proceed to Algorithm C for phenotyping and UPOINT-directed therapy^[1]

Incidental inflammation found with no genitourinary symptoms at all: Category IV (asymptomatic inflammatory prostatitis) — no treatment needed unless an elevated PSA, an infertility workup, or a pre-biopsy indication exists^[1]

Algorithm B — Acute bacterial prostatitis: severity-directed treatment

Suspected/confirmed acute bacterial prostatitis

Assess for urosepsis (hyperpyrexia, prolonged vomiting, severe dehydration, tachycardia, tachypnea, hypotension) and high-risk features (diabetes, immunosuppression, older age, prostatic abscess, severe voiding disorder)^[1]

Urosepsis or high-risk features present

Hospitalize. Empiric IV therapy: aminoglycoside plus ampicillin, OR a broad-spectrum penicillin plus a beta-lactamase inhibitor, OR a 3rd-generation cephalosporin, OR an IV fluoroquinolone, until defervescence and resolution of urosepsis^[1]

Step down to an oral fluoroquinolone once afebrile and clinically improved; complete 2-4 weeks total^[1]

Not severely ill, tolerating oral intake

Outpatient oral fluoroquinolone (levofloxacin) for 2-4 weeks; sulfamethoxazole-trimethoprim only where local E. coli resistance is confirmed under 10-20%^[1]

Younger, sexually active man — STI-likely etiology

Ceftriaxone single dose plus doxycycline 100 mg PO twice daily for 14 days^[3]

Severe obstructive voiding symptoms or urinary retention

Single catheterization or short-term small-caliber urethral catheter; suprapubic tube if a urethral catheter cannot be tolerated^[1]

Refractory to 48-72 hours of appropriate therapy

Image (TRUS or CT) to rule out a prostatic abscess; drain if found^[1]

Algorithm C — Chronic prostatitis/CPPS: localization testing and UPOINT-directed therapy

Chronic pelvic pain and/or recurrent UTI pattern, no acute toxicity

Midstream urine culture; if recurrent UTIs or bacteriuria, proceed to the 4-glass test (or 2-glass pre/post-massage test) for localization^[1]

Infection localized to prostate-specific specimens (EPS/VB3 bacterial count at least 10x VB1/VB2)

Chronic bacterial prostatitis confirmed — fluoroquinolone for 4-6 weeks (see Choose Initial Treatment); alpha-blocker optional add-on for obstructive symptoms^[1]

No infection localized; NIH-CPSI completed

CP/CPPS — phenotype using UPOINT: Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, Tenderness^[1]

Direct multimodal therapy to each positive UPOINT domain simultaneously rather than sequential monotherapy trials^[1]^[5]

Inadequate response after an adequate multimodal trial: reassess phenotype, screen for depression/suicidality, refer to a pain clinic/multidisciplinary team, and reconsider the diagnosis itself^[1]^[2]

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Acute Bacterial Prostatitis — Severe Illness or Urosepsis (Initial Parenteral Therapy)

Continue IV therapy until defervescence and resolution of urosepsis, then step down to an oral fluoroquinolone to complete 2-4 weeks total. Hospitalization is mandatory for hyperpyrexia, prolonged vomiting, severe dehydration, tachycardia, tachypnea, or hypotension, and recommended for high-risk patients (diabetes, immunosuppression, older age, prostatic abscess, severe voiding disorder).

Drug	Dosage	Adverse effects	Drug interactions	Comments
Piperacillin-Tazobactam	Adults: 3.375-4.5 g IV every 6-8 hours	GI upset, hypersensitivity, electrolyte disturbances	Dose reduction needed in renal impairment	Broad-spectrum penicillin/beta-lactamase inhibitor option; one of several acceptable initial IV regimens.
Ceftriaxone	Adults: 1-2 g IV or IM once daily	Injection-site pain, hypersensitivity, rare biliary sludging	Do not co-administer with calcium-containing IV solutions	Third-generation cephalosporin option; does not reliably cover Pseudomonas — confirm local antibiogram/culture.
Ceftazidime	Adults: 1-2 g IV every 8 hours	GI upset, hypersensitivity, neurotoxicity at high doses in renal impairment	Dose-adjust in renal impairment	Preferred third-generation cephalosporin specifically when Pseudomonas coverage is needed.
Gentamicin	Adults: Weight-based IV dosing per local protocol	Nephrotoxicity, ototoxicity	Additive nephrotoxicity with other nephrotoxins; requires therapeutic drug monitoring	Paired with ampicillin for broad empiric gram-negative and enterococcal coverage; monitor renal function and levels.
Ampicillin	Adults: 1-2 g IV every 4-6 hours	Hypersensitivity, GI upset	Reduced efficacy with concurrent bacteriostatic agents	Paired with gentamicin for enterococcal and broad gram-negative coverage in the initial empiric regimen.

Acute Bacterial Prostatitis — Outpatient, Mild-to-Moderate Illness

For patients who are not severely ill and are tolerating oral intake.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Levofloxacin	Adults: 500 mg PO once daily for 2-4 weeks	GI upset, tendinopathy risk, QTc prolongation, peripheral neuropathy	Reduced absorption with antacids/metal cations/dairy; avoid with other QTc-prolonging drugs	Preferred oral agent given confirmed availability and once-daily dosing; achieves favourable prostate-tissue penetration (see Choose Initial Treatment).
Ciprofloxacin	Adults: 500 mg PO twice daily for 2-4 weeks	GI upset, tendinopathy, QTc prolongation, CNS effects	Reduced absorption with antacids/metal cations/dairy	Historically the most extensively studied fluoroquinolone for prostatitis; only combination ciprofloxacin products exist in this platform's drug database, so it is presented here unlinked.
Sulfamethoxazole-Trimethoprim	Adults: 1 DS tablet (800/160 mg) PO twice daily for 2-4 weeks	Rash, hyperkalemia, hematologic effects, photosensitivity	Increased INR with warfarin; hyperkalemia risk with ACE inhibitors/ARBs/potassium-sparing diuretics	No longer first-line empiric therapy where local E. coli resistance exceeds 10-20%; penetration is driven mainly by the trimethoprim component (see Choose Initial Treatment).

Acute Bacterial Prostatitis — Likely Sexually Transmitted Etiology (Younger, Sexually Active Men)

Mirrors this platform's Epididymitis chapter regimen and partner-management protocol — the same ascending-STI logic applies when the infection has reached the prostate itself.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Ceftriaxone	Single dose: 250 mg IM	Injection-site pain, hypersensitivity, rare biliary sludging	Do not co-administer with calcium-containing IV solutions	Single-dose gonorrhea coverage, paired with doxycycline below.
Doxycycline	Adults: 100 mg PO twice daily for 14 days	GI upset, photosensitivity, esophageal irritation	Reduced absorption with antacids/calcium/iron/dairy	Chlamydia coverage; complete the full 14-day course even once pain and voiding symptoms improve.

Chronic Bacterial Prostatitis

Because of their unique, favourable pharmacokinetic properties, fluoroquinolones are the agents of choice; treatment-refractory patients with a confirmed, prostate-localized uropathogen may need intermittent treatment of recurrences or low-dose suppressive therapy (see Treatment Failure / Next Step).

Drug	Dosage	Adverse effects	Drug interactions	Comments
Levofloxacin	Adults: 500 mg PO once daily for 4-6 weeks	GI upset, tendinopathy risk, QTc prolongation, peripheral neuropathy	Reduced absorption with antacids/metal cations/dairy; avoid with other QTc-prolonging drugs	First-line; the 4- to 6-week duration reflects genuinely reduced antibiotic penetration into chronically inflamed prostate tissue compared with the acutely inflamed gland of ABP.
Sulfamethoxazole-Trimethoprim	Adults: 1 DS tablet (800/160 mg) PO twice daily for 8-12 weeks	Rash, hyperkalemia, hematologic effects, photosensitivity	Increased INR with warfarin; hyperkalemia risk with ACE inhibitors/ARBs/potassium-sparing diuretics	Reserved for a confirmed fluoroquinolone-resistant pathogen; the longer 8- to 12-week course compensates for weaker prostate-tissue penetration than a fluoroquinolone.
Fosfomycin	Loading: 3 g PO every 24 hours for 1 week Maintenance: 3 g PO every 48-72 hours for a total of 6-12 weeks	GI upset, headache	Reduced absorption with metoclopramide	For multidrug-resistant, including ESBL-producing, E. coli; penetrates the prostate by a mechanism independent of the ion-trapping pathway fluoroquinolones rely on.
Azithromycin	Adults: Per product monograph, specialist-directed regimen	GI upset, QTc prolongation	Numerous CYP3A4 interactions (weaker than clarithromycin)	For confirmed or strongly suspected Chlamydia-associated chronic bacterial prostatitis.
Clarithromycin	Adults: Per product monograph, specialist-directed regimen	GI upset, metallic taste, QTc prolongation	Significant CYP3A4 interactor — review the full medication list before starting	Macrolide alternative to azithromycin for atypical-organism-associated chronic bacterial prostatitis.

Auxiliary Therapy for Acute and Chronic Bacterial Prostatitis

Alpha-blockers do not treat the infection itself but reduce urinary retention risk and improve voiding comfort; NSAIDs address pain and, in ABP, fever.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Tamsulosin	Adults: 0.4 mg PO once daily	Dizziness, retrograde ejaculation	None significant	Consider for moderately severe obstructive voiding symptoms to reduce urinary retention risk and facilitate micturition.
Ibuprofen	Adults: 400-600 mg PO every 6-8 hours with food	GI upset/bleeding risk, renal effects with prolonged use	Increased bleeding risk with anticoagulants; avoid with other NSAIDs	First-line for pain and fever while antibiotics take effect.
Naproxen	Adults: 250-500 mg PO twice daily with food	GI upset/bleeding risk, renal effects with prolonged use	Increased bleeding risk with anticoagulants; avoid with other NSAIDs	Longer dosing interval alternative to ibuprofen.

Chronic Prostatitis/Chronic Pelvic Pain Syndrome — UPOINT-Directed Multimodal Therapy

Organized by the UPOINT domain each agent targets — direct therapy to a patient's actual positive domains simultaneously rather than trialling one drug class after another in sequence (see Choose Initial Treatment and Assessment & Diagnosis).

Drug	Dosage	Adverse effects	Drug interactions	Comments
Tamsulosin	Adults: 0.4 mg PO once daily	Dizziness, retrograde ejaculation	None significant	Urinary domain — voiding symptoms; must be continued at least 6 (likely 12) weeks before judging effect, and works best as part of multimodal therapy rather than as monotherapy.
Alfuzosin	Adults: 10 mg PO once daily after the same meal	Dizziness, headache, fatigue	None significant	Urinary domain — the best-studied alpha-blocker specifically in CP/CPPS randomized trials.
Oxybutynin	Adults: Immediate-release 5 mg PO 2-3 times daily, or extended-release 5-30 mg PO once daily, titrated	Dry mouth, constipation; more CNS effects (confusion) than newer antimuscarinics	Additive anticholinergic burden with other anticholinergic drugs	Urinary domain — for bothersome storage symptoms (frequency, urgency) without a significantly elevated post-void residual.
Mirabegron	Adults: 25 mg PO once daily; may increase to 50 mg once daily	Hypertension, headache, urinary tract infection	None significant	Urinary domain — beta-3 agonist alternative to an antimuscarinic for storage-predominant symptoms; monitor blood pressure.
Phenazopyridine	Adults: Short courses per product monograph	Orange-red urine discoloration; can mask hematuria on visual inspection	None significant	Urinary domain — short-term urinary analgesic for dysuria; does not treat the underlying cause and should not be continued long-term.
Finasteride	Adults: 5 mg PO once daily for at least 6 months before judging effect	Sexual dysfunction; rare serious muscle-related effects	None significant	Organ-specific domain — older men with a demonstrably enlarged prostate; not primary monotherapy. See the Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia chapter for the full PSA-suppression and pregnancy-exposure counselling points.
Tadalafil	Adults: 5 mg PO once daily	Headache, dyspepsia, flushing, back pain; rare vision or hearing loss	Contraindicated with nitrates/guanylate cyclase stimulators	Organ-specific/sexual domain — for coexisting erectile dysfunction only; does not address pain or voiding symptoms on its own.
Amitriptyline	Adults: Low dose per product monograph, titrated	Anticholinergic effects, sedation, dry mouth	Additive sedation/anticholinergic burden with other such drugs	Neurologic/systemic domain — pain with a neuropathic quality; low, chronic-pain-range dose, titrated to tolerability.
Gabapentin	Adults: Per product monograph, titrated to tolerability and renal function	Dizziness, somnolence, peripheral edema	Additive CNS depression with other sedating drugs	Neurologic/systemic domain — neuropathic-type pain; class alternative to pregabalin.
Pregabalin	Adults: Per product monograph, titrated to tolerability and renal function	Dizziness, somnolence, peripheral edema	Additive CNS depression with other sedating drugs	Neurologic/systemic domain — the specific agent studied in a randomized controlled trial for CP/CPPS-associated pain.
Baclofen	Adults: Per product monograph, titrated	Sedation, dizziness, weakness	Additive CNS depression with other sedating drugs	Tenderness domain — palpable pelvic floor spasm/trigger points, alongside pelvic floor physical therapy; avoid abrupt discontinuation after regular use.
Cyclobenzaprine	Adults: Per product monograph	Sedation, dry mouth, dizziness	Additive sedation/anticholinergic burden with other such drugs; avoid with MAOIs	Tenderness domain — alternative skeletal muscle relaxant for pelvic floor spasm.
Celecoxib	Adults: Per product monograph	GI upset (less than non-selective NSAIDs), cardiovascular risk with prolonged use	Avoid in sulfonamide allergy; increased bleeding risk with anticoagulants	COX-2-selective adjunct analgesic option when a GI-sparing NSAID is preferred.

References

Prostatitis — Canadian Urological Association (Nickel JC). Can Urol Assoc J 2011;5(5):306-15, doi:10.5489/cuaj.11211
Chronic Prostatitis and Chronic Pelvic Pain Syndrome in Men — StatPearls Publishing (Pendegast HJ, Leslie SW, Rosario DJ). StatPearls, updated January 11, 2024
Acute Bacterial Prostatitis — StatPearls Publishing (Davis NG, Silberman M). StatPearls, updated May 22, 2023
Ejaculation increases the serum prostate-specific antigen concentration — Urology (Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE). Urology 1996;47(4):511-516
Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome — American Urological Association (Lai HH, Pontari MA, Argoff CE, et al.). J Urol 2025;214(2):127-137
Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli — Canadian Journal of Infectious Diseases and Medical Microbiology (Zhanel GG, Zhanel MA, Karlowsky JA). Can J Infect Dis Med Microbiol 2018;2018:1404813
Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review — Infectious Diseases and Therapy (Ge R, Nian X, Liu B, Yang Y, Wang Z). Infect Dis Ther 2026;15(5):1203-1248
Male Chronic Pelvic Pain: AUA Guideline: Part I Evaluation and Management Approach — American Urological Association (Lai HH, Pontari MA, Argoff CE, et al.). J Urol 2025;214(2):116-126

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.